Mode
Text Size
Log in / Sign up
Phase 4 Completed N=1,554 Randomized Single-blind Treatment

The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial

Source: ClinicalTrials.gov NCT03668236 ↗
Enrolled (actual)
1,554
Serious AEs
30.0%
Results posted
Feb 2025
Primary outcomePrimary: 90-day Mortality — 323; 329 Participants
◆ Published Evidence
Highly cited
110citations · ~18 / year
Lower vs Higher Fluid Volumes During Initial Management of Sepsis: A Systematic Review With Meta-Analysis and Trial Sequential Analysis.
Chest · 2020 · Likely link

Summary

The purpose of this trial is to assess patient important benefits and harms of IV fluid restriction vs. standard care fluid therapy in patients with septic shock.

Linked Publications (5)

  • Lower vs Higher Fluid Volumes During Initial Management of Sepsis: A Systematic Review With Meta-Analysis and Trial Sequential Analysis.
    Chest · 2020 · 110 citations · Likely link
  • Long-term effects of restriction of intravenous fluid in adult ICU patients with septic shock.
    Intensive care medicine · 2023 · 26 citations · Open access · Likely link
  • Long-term patient-important outcomes after septic shock: A protocol for 1-year follow-up of the CLASSIC trial.
    Acta anaesthesiologica Scandinavica · 2020 · 5 citations · Open access · Likely link
  • Effects of IV Fluid Restriction According to Standard Fluid Treatment Intensity Across Conservative Versus Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care (CLASSIC) Trial Sites.
    Critical care medicine · 2025 · 3 citations · Likely link
  • Effects of IV fluid restriction according to site-specific intensity of standard fluid treatment-protocol.
    Acta anaesthesiologica Scandinavica · 2024 · 1 citation · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
90-day Mortality
323; 329
SECONDARY
Number of Participants With One or More Serious Adverse Events (SAEs) in the ICU
221; 238
SECONDARY
Number of Participants With One or More Serious Adverse Reactions (SARs) to IV Crystalloids in the ICU.
31; 32
SECONDARY
Days Alive at Day 90 Without Life Support (Vasopressor / Inotropic Support, Invasive Mechanical Ventilation or Renal Replacement Therapy)
77; 77
SECONDARY
Days Alive and Out of Hospital at Day 90
21; 33
SECONDARY
All-cause Mortality at 1-year After Randomisation
385; 383
SECONDARY
Health-related Quality of Life 1 Year After Randomisation
0; 0
SECONDARY
Cognitive Function 1-year After Randomisation
0; 0

Eligibility Criteria

Inclusion Criteria

All the following criteria must be fulfilled:

  • Aged 18 years or above
  • Admitted to the ICU or plan to be admitted to the ICU regardless of trial participation
  • Septic shock defined according to the Sepsis-3 criteria:
  • Suspected or confirmed site of infection or positive blood culture AND
  • Ongoing infusion of vasopressor/inotrope agent to maintain a mean arterial blood pressure of 65 mmHg or above AND
  • Lactate of 2 mmol/L or above in any plasma sample performed within the last 3-hours
  • Have received at least 1 L of IV fluid (crystalloids, colloids or blood products) in the last 24-hours prior to screening.

Exclusion Criteria

Patients who fulfil any of the following criteria will be excluded:

  • Septic shock for more than 12 hours at the time of screening as these patients are no longer early in their course
  • Life-threatening bleeding as these patients need specific fluid/blood product strategies
  • Acute burn injury of more than 10% of the body surface area as these patients need a specific fluid strategy
  • Known pregnancy
  • Consent not obtainable as per the model approved for the specific site
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03668236) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search